VivoSeq
Neurology

Peripheral Neuropathy

162

Pipeline Programs↗

40

Active Trials↗

73

Companies Involved↗

Peripheral Neuropathy is a highly competitive landscape with 162 programs across 73 companies. The most active players are Takeda, Teva, Tanabe Pharma Corporation. 21 therapies are approved with 33 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

78/100

Pipeline Velocity

39/100

Mech. Concentration

9/100

Completion Rate

77/100

Attrition Rate

14/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Takeda logo

Takeda

2 programs

Phase 2Teva logo

Teva

2 programs

Phase 2Tanabe Pharma Corporation logo

Tanabe Pharma Corporation

1 program

Phase 2C

Convergence Pharmaceuticals

1 program

Phase 2T

Targeted Medical Pharma

1 program

Phase 2A

Aegera Therapeutics

1 program

Phase 2

Pipeline

Programs by Phase

Preclinical14

Venlafaxine

Wyeth-Lederle Vaccines

Eribulin

Eisai

Peptide T

National Institute of Mental Health (NIMH)

Thiamine

Universiti Kebangsaan Malaysia Medical Centre

Alpha Lipoic Acid

National Center for Complementary and Integrative Health (NCCIH)

Phase 112

Trimetazidine

IRCCS San Raffaele

Roflumilast

AstraZeneca

Pantoprazole

Wyeth-Lederle Vaccines

Coenzyme Q10

Mclean Hospital

Nilotinib

Azurity Pharmaceuticals

Phase 282

Dextromethorphan

Pfizer

Epoetin Alfa

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Candesartan

AstraZeneca

Paclitaxel

Teva

LY3819253

Eli Lilly

Phase 333

Capsaicin

Averitas Pharma, Inc.

Glutamine

Sanofi

Lamotrigine

Glaxo Dba Glaxosmithkline

Duloxetine Hydrochloride

Eli Lilly

Magnesium Sulfate

Fresenius Kabi Oncology Ltd.

Approved21

Milnacipran

AbbVie

Bortezomib

Shilpa Grover, MD, MPH

Gabapentin

Viatris Specialty LLC

Fluorouracil

Elorac, Inc.

Duloxetine

Alnylam Pharmaceuticals

Analysis

Modality Breakdown

97%

Small molecule

178 of 183 classified programs — the dominant modality here.

3%ALL OTHERSMonoclonal antibody21%Peptide21%Protein / enzyme1<1%

Small molecule leads; the ring shows all 183 classified programs, each share of the total. Modality classified for 100% of 188 pipeline programs.

Analysis

Trial Status

209

clinical trials

Completed103 · 49%
Unknown status36 · 17%
Terminated23 · 11%
Recruiting17 · 8%
Not yet recruiting13 · 6%
Active, not recruiting10 · 5%
Other7 · 3%

Clinical Trials

Trial Activity

209 trials

Phytocannabinoids for Reducing Chronic Chemotherapy-Induced Peripheral Neuropathy in Breast and Colon Cancer Survivors
Recruiting·—·Phase 2·NCT06731894·120 enrolled
The Possible Protective Role of Ketotifen Against Oxaliplatin Induced Peripheral Neuropathy
Recruiting·TTanta University·Phase 3·NCT05624138·64 enrolled
Efficacy and Safety of Duloxetine in Chinese Solid Tumor Patients with Taxanes-induced Painful Peripheral Neuropathy
Recruiting·—·Phase 2·NCT04970121·100 enrolled
Evaluation of Efficacy and Safety of Suzetrigine (SUZ) for Pain Associated With Diabetic Peripheral Neuropathy
Recruiting·Vertex Pharmaceuticals logoVertex Pharmaceuticals·Phase 3·NCT07231419·734 enrolled
Evaluation of Efficacy and Safety of VX-993 for Pain Associated With Diabetic Peripheral Neuropathy
Recruiting·Vertex Pharmaceuticals logoVertex Pharmaceuticals·Phase 2·NCT06619860·300 enrolled
Fenofibrate Role in the Prophylaxis From Peripheral Neuropathy Induced by Bortezomib, Lenalidomide and Dexamethasone (VRd) Protocol in the Treatment of Patients With Multiple Myeloma (MM)
Recruiting·TTanta University·Phase 4·NCT07025005·44 enrolled
Ozone Treatment in Paresthesia (Numbness, Tingling) Secondary to Chemotherapy-induced Peripheral Neuropathy
Recruiting·—·Phase 2/3·NCT06706544·42 enrolled
Capsaicin 179 mg Patch Versus Oral Duloxetine in Patients With Chemotherapy-induced Peripheral Neuropathy
Recruiting·IInstitut Cancerologie de l'Ouest·Phase 3·NCT05840562·274 enrolled
Effect of Melatonin in Patients With Diabetic Peripheral Neuropathy
Recruiting·—·Phase 2·NCT07036796·60 enrolled
GM1 Prophylaxis for Nab-paclitaxel-associated Chemotherapy-induced Peripheral Neuropathy (CIPN) in Patients With Breast Cancer
Recruiting·Qilu Pharmaceutical Co., Ltd. logoQilu Pharmaceutical Co., Ltd.·Phase 3·NCT06994507·352 enrolled
Study on the Efficacy and Safety of Mecobalamin in Preventing Taxane-related Peripheral Neuropathy
Recruiting·QQinghai Red Cross Hospital·Phase 3·NCT07423390·326 enrolled
The Role of Coenzyme Q10 in the Prophylaxis of Oxaliplatin Induced Peripheral Neuropathy in Patients With Colorectal Cancer
Recruiting·Ttoqa saad mohammed mohammed·Phase 1·NCT06856447·22 enrolled
Evaluation of Efficacy and Safety of Suzetrigine for Pain Associated With Diabetic Peripheral Neuropathy
Recruiting·Vertex Pharmaceuticals logoVertex Pharmaceuticals·Phase 3·NCT06628908·1,100 enrolled
Effectiveness of Cryotherapy Combined With Compression Therapy for Preventing Chemotherapy-induced Peripheral Neuropathy
Recruiting·PPeking University·N/A·NCT05341141·102 enrolled
Omega-3 Fatty Acid Lipidomics in Diabetes Peripheral Neuropathy
Recruiting·UUniversity of Iowa·Phase 1/2·NCT05169060·100 enrolled
Page 1 of 14

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)